drugset / Trial / NCT05931276
CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
RandomizedParallel-groupOpen-labelTreatment
Summary
The investigators aim to determine, using a point-of-care randomized controlled trial design, if hemodialysis patients, who are randomized to metoprolol succinate (a dialyzable, beta-1 selective beta blocker), have an improved cardiovascular outcome compared to those randomized to carvedilol (a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties). The investigators will also examine intervention practices to identify components that best support engagement and sustainability.
Timeline
- Start
- 2024-05-22
- Primary completion
- 2026-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Carvedilol | Other / unclassified | 3.125 mg | — |
| Comparator | Carvedilol | Other / unclassified | 6.25 mg | — |
| Comparator | Carvedilol | Other / unclassified | 12.5 mg | — |
| Comparator | Carvedilol | Other / unclassified | 25 mg | — |
| Comparator | Metoprolol | Other / unclassified | 12.5 mg | — |
| Comparator | Metoprolol | Other / unclassified | 25 mg | — |
| Comparator | Metoprolol | Other / unclassified | 50 mg | — |
| Comparator | Metoprolol | Other / unclassified | 100 mg | — |
| Comparator | Metoprolol | Other / unclassified | 200 mg | — |